特拉唑嗪联合前列癃闭通胶囊治疗慢性前列腺炎临床研究

目的 观察特拉唑嗪联合前列癃闭通胶囊治疗慢性非细菌性前列腺炎(NBP)的疗效.方法 102例NBP患者随机分为治疗组54例和对照组48例,治疗组口服特拉唑嗪+前列癃闭通胶囊；对照组口服特拉唑嗪+左氧氟沙星.分别观察治疗前、治疗4周、8周后慢性前列腺炎症状指数评分(NIH-CPSI)、前列腺按摩液(EPS)常规检查及尿流率的变化.结果 治疗4周后,两组NIH-CPS总评分、症状评分、生活质量评分、疼痛症状评分及排尿症状评分较治疗前均明显改善(t=14.80、16.20、6.15、8.67、10.00、16.47、14.62、8.79、10.77、10.86,均P＜0.01)；治疗8周后,对照组NIH-CPS评分较治疗4周时无明显改善(均P＞0.05),治疗组较治疗4周时有明显改善(t=2.76、2.71、2.75、2.72、2.73,均P＜0.01).治疗4周后,两组AFR、MFR较治疗前均增加(t=11.56、11.84、13.85、12.80,均P＜0.01)；但两组间差异均无统计学意义(均P＞0.05).结论 特拉唑嗪联合前列癃闭通胶囊治疗NBP可减轻临床症状,提高生活质量.

Clinical application of terazosin combined with Qianlielongbitong in the treatment of chronic non-bacterial prostatitis

Objective To investigate the effect and mechanism of terazosin combined with Qianlielongbitong in the treatment of non-bacterial prostatitis. Methods One hundred and two patients with non-bacterial prostatitis were divided into two groups：one group was treated with terazosin 4 mg qn and Qianlielongbitong, while the other group was treated with terazosin and Levoofloxacin. We compared three indices of chronic prostatitis symptom index （NIH-CPSI）, prostatic secretion examination（EPS） and urodynamic data in three different steps：before treatment, af- ter 4-week treatment and after 8-week treatment. Results The NIH-CPSI of both groups was greatly improved after treatment （all P 〈 0.01 ）. Inside the treatment group, the NIH-CPSI after 8-week treatment was better than that after 4- week treatment（ all P 〈 0.01 ）. However, in both groups, there was no significant difference between the index after 8- week treatment and the one after 4 week. EPS, AFR and MFR were greatly improved in both groups （ all P 〈 0. 01 ）. Conclusion Terazosin can relieve the clinical symptom, and improve the life quality.